Abstracts tagged "Biologic agents"

Abstract Number: 1561 • 2015 ACR/ARHP Annual Meeting
The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Doo-Ho Lim¹, Seokchan Hong², Soo Min Ahn², Byeongzu Ghang³, Wook Jang Seo⁴, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Osteoporosis is more frequently observed in patients with rheumatoid arthritis (RA) than in general population. Bisphosphonate (BP), which suppresses bone resorption by inhibiting osteoclast…
Abstract Number: 2435 • 2015 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Katerina Jarosova¹, Katerina Andelova², Karel Hejduk³, Michal Uher³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²clinical, Institute for the Care for Mother and Child, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: Biologic drugs are effective therapeutic option in patients with juvenile idiopathic arthritis (JIA). However, data regarding the use during pregnancy and breastfeeding in adult…
Abstract Number: 2887 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
Atul A. Deodhar¹, Dominique Baeten², Joachim Sieper³, Brian Porter⁴, Albert Widmer⁵ and Hanno Richards⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in 2 Phase 3, randomized, double-blind, placebo (PBO)-controlled studies, MEASURE…
Abstract Number: 187 • 2015 ACR/ARHP Annual Meeting
Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound
Kazuhiro Yokota¹, Takuma Tsuzuki Wada², Yuji Akiyama² and Toshihide Mimura³, ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Irama, Japan, ²Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: The detection of power Doppler (PD) ultrasound signals in joints may be considered as the presence of joint inflammation, i.e., synovitis which is a…
Abstract Number: 707 • 2015 ACR/ARHP Annual Meeting
Change of Enthesial Involvement Under Treatment Was Independent from the Therapeutic Strategy in Patients with Axial Spondyloarthritis within the Scqm Cohort
Ruediger Mueller¹, Toni Kaegi², Nicole Graf³, Johannes von Kempis⁴ and J.J. Luime⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³graf biostatistics, Winterthur, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…
Abstract Number: 1571 • 2015 ACR/ARHP Annual Meeting
How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As rheumatologists search for new targets to improve immunosuppressive outcomes, the autonomic nervous system (ANS) as a co-factor in autoimmune disease expression has gained…
Abstract Number: 2507 • 2015 ACR/ARHP Annual Meeting
A Quality Indicator for the Screening of Latent Tuberculosis Infection and the Result of Follow-up Interferon-Gamma-Release Assays in Patients with Rheumatic Disease Receiving Biologic Agents in a Japanese Hospital
Yasuhiro Suyama^1,2, Mitsumasa Kishimoto², Chisun Min³, Yuko Kataoka², Masei Suda², Ryo Rokutanda², Yukio Matsui², Ken-ichi Yamaguchi², Tokutaro Tsuda², Shunya Kaneshita², Hisanori Shimizu² and Masato Okada², ¹Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Infection is one of the most devastating side effects of biologic agents use, particularly early on in the course of therapy. Prevention is considered…
Abstract Number: 2890 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naïve Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
Dominique Baeten¹, Ricardo Blanco², Piet Geusens³, Joachim Sieper⁴, Tseng Jui-Cheng⁵, Ruvie Martin⁶, Brian Porter⁶ and Hanno Richards⁷, ¹Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Maastricht University, Maastricht, Netherlands, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Anti‒TNFs are the only biologics currently approved for ankylosing spondylitis (AS). There is a significant unmet need in those patients (pts) with an inadequate…
Abstract Number: 264 • 2015 ACR/ARHP Annual Meeting
Clinical Phenotype and Response to Treatment in Adult-Onset Still’s Disease with MEFV Variants
Fumiaki Nonaka¹, Toshimasa Shimizu², Katsumi Eguchi³, Masataka Umeda⁴, Yukitaka Ueki⁵, Keita Fujikawa⁶, Akinari Mizokami⁷, Munetoshi Nakashima⁸, Michio Yasunami⁹, Naoki Iwamoto⁴, Atsushi Kawakami², Yuka Jiuchi¹⁰ and Kiyoshi Migita¹⁰, ¹Department of Rheumatology and Metabloism, Sasebo City General Hospital, Sasebo, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁶Arthritis and Connective Tissue Disease, Isahaya Health Insurance General Hospital, Isahaya, Japan, ⁷Department of Rheumatology, Isahaya Health Insurance General Hospital, Isahaya, Japan, ⁸Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Nagasaki University Institute of Tropical Medicine (NEKKEN), Nagasaki, Japan, ¹⁰Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. Patients with Familial Mediterranean Fever…
Abstract Number: 959 • 2015 ACR/ARHP Annual Meeting
Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Timothy Beukelman², Esi Morgan-DeWitt³, Kelly L. Mieszkalski⁴, Thomas Brent Graham⁵, Maria F. Ibarra⁶, Norman Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵, Laura Schanberg¹⁶ and the CARRA Registry Investigators, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Pediatric Rheumatology, Univ of Chicago, Chicago, IL, ¹⁰Rheumatology, Emory University, Atlanta, GA, ¹¹Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatrics, Seattle Children's Hospital, Seattle, WA, ¹³Pediatric Rheumnatology, St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁵Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Systemic JIA (sJIA) in usual practice is commonly treated with several agents, including glucocorticoids (GC), methotrexate (MTX) and biologic agents, most commonly IL1 or…
Abstract Number: 1603 • 2015 ACR/ARHP Annual Meeting
Safety of Biologic and Non-Biologic Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis C Infection
Jeffrey R. Curtis^1,2, Mary Jane Burton³, Shou Yang¹, Lang Chen¹, Ted R. Mikuls⁴, Jasvinder A. Singh², Kevin L. Winthrop⁵ and John Baddley^2,6, ¹University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VAMC, Birmingham, AL, ³Jackson VAMC, Jackson, MS, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oregon Health and Science University, Portland, OR, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Among patients with rheumatoid arthritis and hepatitis C virus (HCV) infection, the impact of biologic and nonbiologic DMARD therapy on hepatotoxicity has received limited study.…
Abstract Number: 2524 • 2015 ACR/ARHP Annual Meeting
Longterm Follow-up of Children Born to Mothers with Chronic Arthritides and Exposed to Anti-TNF Alfa Agents during Pregancy and Breastfeeding: A Case-Control Study
Rossella Reggia¹, Laura Andreoli¹, Chiara Bazzani¹, Maria Grazia Lazzaroni¹, Giovanna Mazza¹, Michele Agosti¹, Roberto Gorla², Marco Taglietti², Andrea Lojacono³, Mario Motta⁴ and Angela Tincani⁵, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ³Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Neonatal Intensive Care Unit, University and Spedali Civili of Brescia, Brescia, Italy, ⁵Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Anti-TNFalfa agents have been used to control disease activity of patients with Chronic Arthritides (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis) during the wash-out period…
Abstract Number: 2896 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Baeten¹, Jurgen Braun², Joachim Sieper³, Maxime Dougados⁴, Atul A. Deodhar⁵, Xenofon Baraliakos⁶, Brian Porter⁷, Yankun Gong⁸ and Hanno Richards⁹, ¹1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, Herne, Germany, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Oregon Health and Sciences University, Portland, OR, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Beijing Novartis Pharma Co. Ltd., Beijing, China, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks (wks) in the randomized, double-blind, placebo (PBO)-controlled,…
Abstract Number: 426 • 2015 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen⁴, Melissa L. Mannion⁵, Kenneth G. Saag⁴, Jie Zhang⁶ and Jeffrey R. Curtis⁴, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are highly effective for the treatment of juvenile idiopathic arthritis (JIA) but have the potential risk of increased serious infections. Using observational…
Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting
Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
T. W. J. Huizinga¹, Anastas Batalov², Rumen Stoilov³, Eric Lloyd⁴, Thomas Wagner⁵, Didier Saurigny⁶, Bernard Souberbielle⁶ and Ehsanollah Esfandiari⁶, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²UMHAT Kaspela, Plovdiv, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Takeda Pharmaceuticals, Deerfield, IL, ⁵Takeda Pharmaceuticals, Zurich, Switzerland, ⁶Takeda Pharmaceuticals, London, United Kingdom
Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].